JP2010529063A - 血圧の調節のための経口治療のための、単相医薬複合調製物（ジエノゲスト（ｄｉｅｎｏｇｅｓｔ）およびエチニルエストラジオール） - Google Patents

血圧の調節のための経口治療のための、単相医薬複合調製物（ジエノゲスト（ｄｉｅｎｏｇｅｓｔ）およびエチニルエストラジオール） Download PDF

Info

Publication number: JP2010529063A
Authority: JP; Japan
Prior art keywords: dienogest; ethinylestradiol; blood pressure; daily dosage; daily
Prior art date: 2007-07-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

JP2010510703A

Other languages

English (en)

Japanese (ja)

Other versions

JP2010529063A6 (ja

Inventor

ツィマーマン，トマス

ミットマン，カトリン

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bayer Pharma AG

Original Assignee

Bayer Schering Pharma AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-31

Filing date

2008-07-15

Publication date

2010-08-26

2008-07-15 Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG

2010-08-26 Publication of JP2010529063A publication Critical patent/JP2010529063A/ja

2010-12-02 Publication of JP2010529063A6 publication Critical patent/JP2010529063A6/ja

Status Withdrawn legal-status Critical Current

Links

230000029865 regulation of blood pressure Effects 0.000 title claims abstract description 6
229940007694 dienogest and ethinylestradiol Drugs 0.000 title claims description 5
238000002360 preparation method Methods 0.000 title 1
238000002560 therapeutic procedure Methods 0.000 title 1
AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 claims abstract description 29
229960003309 dienogest Drugs 0.000 claims abstract description 29
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims abstract description 28
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims abstract description 27
229960002568 ethinylestradiol Drugs 0.000 claims abstract description 27
239000003433 contraceptive agent Substances 0.000 claims abstract description 8
229940124558 contraceptive agent Drugs 0.000 claims abstract 4
238000011282 treatment Methods 0.000 claims description 13
239000003826 tablet Substances 0.000 claims description 11
239000000902 placebo Substances 0.000 claims description 9
229940068196 placebo Drugs 0.000 claims description 9
239000007941 film coated tablet Substances 0.000 claims description 7
230000002254 contraceptive effect Effects 0.000 claims description 6
238000000034 method Methods 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 4
238000013268 sustained release Methods 0.000 claims description 4
239000012730 sustained-release form Substances 0.000 claims description 4
238000004090 dissolution Methods 0.000 claims description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
238000007922 dissolution test Methods 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
239000007888 film coating Substances 0.000 claims description 2
238000009501 film coating Methods 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
239000000825 pharmaceutical preparation Substances 0.000 claims description 2
229940127557 pharmaceutical product Drugs 0.000 claims description 2
239000002904 solvent Substances 0.000 claims description 2
238000003756 stirring Methods 0.000 claims description 2
230000036772 blood pressure Effects 0.000 abstract description 21
206010020772 Hypertension Diseases 0.000 abstract description 9
230000000694 effects Effects 0.000 abstract description 7
230000002411 adverse Effects 0.000 abstract description 5
229940127234 oral contraceptive Drugs 0.000 abstract description 5
239000003539 oral contraceptive agent Substances 0.000 abstract description 5
229940083712 aldosterone antagonist Drugs 0.000 abstract description 3
239000002170 aldosterone antagonist Substances 0.000 abstract description 3
230000007774 longterm Effects 0.000 abstract description 2
208000001953 Hypotension Diseases 0.000 description 7
239000000203 mixture Substances 0.000 description 6
230000035488 systolic blood pressure Effects 0.000 description 6
239000011159 matrix material Substances 0.000 description 5
229920000858 Cyclodextrin Polymers 0.000 description 4
239000001116 FEMA 4028 Substances 0.000 description 4
229960004853 betadex Drugs 0.000 description 4
230000036543 hypotension Effects 0.000 description 4
238000012216 screening Methods 0.000 description 4
208000024172 Cardiovascular disease Diseases 0.000 description 3
230000035487 diastolic blood pressure Effects 0.000 description 3
239000008298 dragée Substances 0.000 description 3
239000000890 drug combination Substances 0.000 description 3
102000004881 Angiotensinogen Human genes 0.000 description 2
108090001067 Angiotensinogen Proteins 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000002934 diuretic Substances 0.000 description 2
229960004845 drospirenone Drugs 0.000 description 2
METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
238000005469 granulation Methods 0.000 description 2
230000003179 granulation Effects 0.000 description 2
208000012866 low blood pressure Diseases 0.000 description 2
239000000463 material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000009984 peri-natal effect Effects 0.000 description 2
230000035935 pregnancy Effects 0.000 description 2
229960002256 spironolactone Drugs 0.000 description 2
239000007940 sugar coated tablet Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
DBLOJPKZEOYNBN-SQNIBIBYSA-N (8s,13s,14s)-13-methyl-2,6,7,8,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 DBLOJPKZEOYNBN-SQNIBIBYSA-N 0.000 description 1
YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
206010009269 Cleft palate Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
208000002787 Pregnancy Complications Diseases 0.000 description 1
208000005107 Premature Birth Diseases 0.000 description 1
229960002478 aldosterone Drugs 0.000 description 1
230000001327 anti-mineralocorticoid effect Effects 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
206010009259 cleft lip Diseases 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000001882 diuretic effect Effects 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
239000000945 filler Substances 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
230000005802 health problem Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
208000021822 hypotensive Diseases 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
239000001034 iron oxide pigment Substances 0.000 description 1
210000001847 jaw Anatomy 0.000 description 1
230000036244 malformation Effects 0.000 description 1
239000002394 mineralocorticoid antagonist Substances 0.000 description 1
230000001452 natriuretic effect Effects 0.000 description 1
201000010193 neural tube defect Diseases 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000008520 organization Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
208000012113 pregnancy disease Diseases 0.000 description 1
230000002028 premature Effects 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000036454 renin-angiotensin system Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
-1 spironolactone compound Chemical class 0.000 description 1
208000035581 susceptibility to neural tube defects Diseases 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
206010042772 syncope Diseases 0.000 description 1
230000008346 uterine blood flow Effects 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

Health & Medical Sciences (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

JP2010510703A 2007-07-31 2008-07-15 血圧の調節のための経口治療のための、単相医薬複合調製物（ジエノゲスト（ｄｉｅｎｏｇｅｓｔ）およびエチニルエストラジオール） Withdrawn JP2010529063A (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US95295007P	2007-07-31	2007-07-31
US60/952,940		2007-07-31
DE102007036516		2007-08-01
DE102007036516.2		2007-08-01
PCT/EP2008/005756 WO2009015766A1 (fr)	2007-07-31	2008-07-15	Préparation pharmaceutique combinée monophasique (diénogest et éthinylestradiol) pour la thérapie orale de régulation de la pression artérielle

Publications (2)

Publication Number	Publication Date
JP2010529063A true JP2010529063A (ja)	2010-08-26
JP2010529063A6 JP2010529063A6 (ja)	2010-12-02

Family

ID=70482998

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2010510703A Withdrawn JP2010529063A (ja)	2007-07-31	2008-07-15	血圧の調節のための経口治療のための、単相医薬複合調製物（ジエノゲスト（ｄｉｅｎｏｇｅｓｔ）およびエチニルエストラジオール）

Country Status (3)

Country	Link
JP (1)	JP2010529063A (fr)
CA (1)	CA2681021A1 (fr)
WO (1)	WO2009015766A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060079491A1 (en) *	2004-10-08	2006-04-13	Andreas Sachse	Method of female hormonal contraception using a fixed extended cycle hormonal preparation containing dienogest and ethinyl estradiol
ES2310907T3 (es) *	2005-02-15	2009-01-16	JENAPHARM GMBH & CO. KG	Forma de medicamento peroral solida para la contracepcion, que contiene dienogest y etinilestradiol.
US20060183725A1 (en) *	2005-02-15	2006-08-17	Thomas Graeser	Pharmaceutical preparation for oral contraception

2008
- 2008-07-15 WO PCT/EP2008/005756 patent/WO2009015766A1/fr not_active Ceased
- 2008-07-15 JP JP2010510703A patent/JP2010529063A/ja not_active Withdrawn
- 2008-07-15 CA CA002681021A patent/CA2681021A1/fr not_active Abandoned

Also Published As

Publication number	Publication date
CA2681021A1 (fr)	2009-02-05
WO2009015766A1 (fr)	2009-02-05

Publication	Publication Date	Title
JP7140355B2 (ja)	2022-09-21	エステトロール成分を含有する口腔内崩壊性投与単位
KR100913910B1 (ko)	2009-08-26	호르몬 보충 요법용 드로스피렌온
KR102539030B1 (ko)	2023-05-31	드로스피레논을 포함하는 약학적 조성물 및 피임용 키트
JP2009143959A (ja)	2009-07-02	避妊薬として使用するためのエチニルエストラジオールとドロスピレノンとの組合せ剤
ES2970532T3 (es)	2024-05-29	Anticonceptivo basado en drospirenona para una paciente que presenta exceso de peso
JP2011500793A (ja)	2011-01-06	制吐薬と経口避妊薬との組み合わせ
MD3310345T2 (ro)	2021-07-31	Comprimată orodispersabilă ce conține estetrol
Dubuisson et al.	2002	Acceptability of the levonorgestrel-releasing intrauterine system after discontinuation of previous contraception: results of a French clinical study in women aged 35 to 45 years
JP2012516859A (ja)	2012-07-26	１７α−エストラジオールを含む、口腔内適用系
CN101198332A (zh)	2008-06-11	含有孕激素和/或雌激素和5-甲基-(6s)-四氢叶酸的药物组合物
TW473390B (en)	2002-01-21	A hormonal pharmaceutical composition for correcting oestrogen deficiencies in menopausal women
JP2000515888A (ja)	2000-11-28	経口避妊薬
JP2010523512A (ja)	2010-07-15	新規ドロスピレノン／１７β−エストラジオール投与計画、組み合わせ医薬、およびこの投与計画を行なうためのキット
JP2010529063A6 (ja)	2010-12-02	血圧の調節のための経口治療のための、単相医薬複合調製物（ジエノゲスト（ｄｉｅｎｏｇｅｓｔ）およびエチニルエストラジオール）
JP2010529063A (ja)	2010-08-26	血圧の調節のための経口治療のための、単相医薬複合調製物（ジエノゲスト（ｄｉｅｎｏｇｅｓｔ）およびエチニルエストラジオール）
EP4420720A2 (fr)	2024-08-28	Utilisation de contraceptifs oraux combinés contenant de l'acétate de nomégestrol et de l'estradiol
TWI328453B (en)	2010-08-11	Use of estradiol valerate in combination with dienogest in order to obtain a multi-stage combined preparation with a total of 28 daily doses for the treatment of dysfunctional uterine bleeding in conjunction with oral contraception
US20090035374A1 (en)	2009-02-05	Method of making a single-stage pharmaceutical preparation for oral therapy to regulate blood pressure and kit containing same
DE102008033254B4 (de)	2010-12-02	Verfahren zur Herstellung eines einphasischen pharmazeutischen Präparates zur oralen Therapie der Regulierung des Blutdruckes
WO2025172590A1 (fr)	2025-08-21	Kit contraceptif comprenant des unités posologiques orales contenant de la déhydroépiandrostérone
JPH08508502A (ja)	1996-09-10	骨粗しょう症の治療方法および治療用組成物
Start	0	1 INDICATIONS AND USAGE
Start	0	FULL PRESCRIBING INFORMATION: CONTENTS
Label	0	FDA Label for Officella
HK1232778A1 (en)	2018-01-19	Drospirenone-based contraceptive for a female patient affected with excess weight

Legal Events

Date	Code	Title	Description
2012-01-24	A761	Written withdrawal of application	Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20120123

Date

Code

Title

Description

2012-01-24

A761

Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120123